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a b s t r a c t
Genetic factors only account for up to a third of the cases of Parkinson’s disease (PD), while
the remaining cases are of unknown aetiology. Environmental exposures (such as pesticides
or heavy metals) and the interaction with genetic susceptibility factors (summarized in
the concept of impaired xenobiotic metabolism) are believed to play a major role in the
mechanisms of neurodegeneration. Beside of the classical association studies (e.g. genome-
wide association studies), a novel approach to investigate environmental risk factors are
Mendelian randomisation studies. This review explores the gene-environment interaction
and the gain of Mendelian randomisation studies in assessing causalities of modifiable risk
factors for PD.
# 2019 The Authors. Published by Elsevier Masson SAS. This is an open access article under
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Parkinson’s disease (PD) is the most common movement
disorder and the second most frequent neurodegenerative
disease after Alzheimer’s disease (AD) [1,2]. First described two
centuries ago, the underlying cause of PD still remains
unknown for the majority of the cases, however, there are
recognized factors which increase the risk for PD, including
aging, environmental exposure (pesticides or heavy metals)
and genetic factors (genetic risk variants and monogenic
Mendelian traits) – currently up to 30% of all PD cases can be
referred to a genetic contribution [3].* Corresponding author at: Luxembourg Centre for Systems Biomedici
Luxembourg, 6 avenue du Swing, 4362 Belval, Esch-sur-Alzette, Luxem
E-mail address: rejko.krueger@uni.lu (R. Kru¨ger).
https://doi.org/10.1016/j.neurol.2019.04.010
0035-3787/# 2019 The Authors. Published by Elsevier Masson SAS. Thi
creativecommons.org/licenses/by-nc-nd/4.0/).Fundamentally, the motor symptoms of PD – as a prototype
for neurodegenerative disorders– are mainly characterized by a
progressive loss of dopaminergic neurons linked with an
accumulation of aggregation-prone alpha-synuclein protein.
These intracellular alpha-synuclein inclusions are a more
generalized process affecting different types of neurons in
the central and peripheral nervous system contributing to
the spectrum of non-motor symptoms in PD and forming
the pathognomonic Lewy bodies in affected brain regions
(reviewed in [4]). Therefore, specific clearance pathways are
involved in PD, that include on one hand impaired protein
degradation via the ubiquitin-proteasome system [5] and on
another hand impaired lysosomal clearance of proteins andne (LCBS), Clinical and Experimental Neuroscience, University of
bourg.
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misfolded alpha-synuclein and its prion-like spread within the
central and autonomous nervous system is supposed to be a
critical step in disease progression [4,8,9]. Whether these
aggregates or the preceding (proto-)fibrillary structures of
alpha-synuclein interfere with the neuron’s vital functions is
currently subject of debate [9]. However, the sequestration of
other proteins and transcription factors into aggregates, as well
as impaired mitochondrial function also increase the cells’
vulnerability to excitotoxicity and oxidative stress, leading to
energy depletion. In addition, due to deficiency of the ubiquitin-
proteasome system, the autophagy lysosome pathway plays an
important role for degradation of misfolded proteins and defect
mitochondria [10]. These mechanisms lead in fine to the
activation of the apoptotic cascade and cell death related to
neurodegeneration. Some neuronal populations seem to more
vulnerable to these pathogenic mechanisms than others
within the nervous system, thus determining the clinical
phenotype of the disease according to the preferential sites of
neuronal dysfunction and subsequent degeneration [11,12].
In the last two decades the investigation of rare familial
forms of PD with monogenetic cases showing classical
Mendelian inheritance provided the first major insights into
the underlying molecular mechanisms involved in PD, by
analysing in vitro and in vivo the resulting dysfunction of
the proteins encoded by these genes, e.g. alpha-synuclein.
This allowed to dissect pathophysiological mechanisms of
impaired protein degradation, oxidative stress and mitochon-
drial dysfunction, and therefore rare monogenic forms of PD
served as an entry point to understand the more common
sporadic form of PD [13]. Indeed, some of the mutations
identified in monogenic forms of PD were also observed in
patients without a positive family history or sometimes in
unaffected individuals, so apparently not sufficient to cause
the disease. This indicates reduced penetrance for some of
the mutations. Carriers of the G2019S mutation in the LRRK2
gene are a good example, where patients were diagnosed with
sporadic PD mirroring the reduced penetrance of certain
genetic risk factors [14–20]. Unbiased genome-wide associa-
tion studies (GWAS) have demonstrated a role of more
common genetic variants in the pathogenesis of idiopathicFig. 1 – The graded-risk concept (adaptPD [20–25]. The ‘‘graded risk’’ concept (Fig. 1) includes
Mendelian mutations, low frequency genetic variants and
common polymorphisms and introduces the concept of a
continuum from more common genetic variants to rare
disease-causing mutations with an associated more or less
strong impact on the expressivity and contribution to the
development of the disease [3,26].
Besides the participation of genetic susceptibility factors
in the pathogenesis of neurodegeneration, these findings on
reduced penetrance and potential polygenic contribution to
disease risk indicate an important role of additional, most
probably environmental, risk factors and an important
interplay between both genetic and environmental factors
in modulating the clinical expression of the disease [27].
2. Gene-environment interactions
2.1. Aging and DNA methylation
Aging, at the cellular level, reflects an accumulation of
changes affecting the physiological functioning of the cell
and the whole organism, leading to an increased vulnerability
to death. ‘‘Chronologic age’’ does not necessarily reflect
necessarily ‘‘biological age’’, as additional variables such as
individual genetic background, lifestyle and disease processes
influence cellular aging. Hallmarks of aging are genetic
alterations including telomere attrition, increased genomic
instability and epigenetic alterations involving changes in
DNA methylation patterns, histone modifications and chro-
matin remodeling [28].
Different biomarkers previously proposed for defining the
biological age of a specific cell or tissue, such as telomere length
[29] or age-dependent deletions of mitochondrial DNA [30], were
insufficient in their precision (e.g. sensitivity, specificity) and
practicality (e.g. accessibility, cost-effectiveness) [31]. Epigenetic
changes, especially the DNA methylation status provides a
more reliable biomarker in this regard [32–34]. Especially some
CpG sites (5’-cytosine-phosphate-guanine-3’ sites) exhibit more
linear DNA methylation changes throughout aging and are thus
valuable biomarkers for age prediction [35–37].ed from Manolio et al., 2009; [26]).
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epigenome due to random changes in methylation (or errors in
the maintenance of the epigenome) over a lifespan – is
influenced substantially by environmental factors, as shown
in twin studies [36,37]. This is believed to cause the individual
susceptibilities, prognoses, treatment outcomes and in a larger
sense the individual clinical phenotypes of common diseases.
Over time, the accumulation of epigenetic changes – or
epimutations – is believed to induce instability of the genome,
to facilitate genetic mutations and finally pathological pro-
cesses defining a disease. These changes in DNA methylation
and their effect on gene expression give us new insight in age-
related diseases such as PD [38,39].
2.2. Gene-environment interaction
Within the last two decades, genetic causes for PD have more
and more come to the forefront in PD research [40]. However,
most cases cannot be explained yet by a monogenetic form of
PD, nor by risk variants. Inversely, even though environmental
factors are recognized to contribute to PD, not everyone with PD
has been exposed to one of the currently known environmental
risk factors and vice versa not everyone exposed to an environ-
mental risk factor is developing the disease. Commonly,
pesticides are thought to alter mitochondrial function and
increase oxidative stress in dopaminergic neurons, but also
to accelerate the formation of alpha-synuclein fibrils and
interfere with the function of the ubiquitin-proteasome system
[41–43]. Professional or occupational pesticide usage may
increase expression of the dopamine transporter (DAT) and
lead to an accumulation of toxicants in dopaminergic neurons,
affecting dopaminergic neurotransmission in subjects carrying
DAT susceptibility alleles [44,45]. Exposure to organophospha-
tes of subjects carrying polymorphisms in the ACHE/PON1
locus might increase the risk for insecticide-induced PD via a
neurotransmission imbalance due to impaired acetylcholines-
terase (AChE) and paraoxonase (PON1) activity (and in fine
impaired organophosphate degradations) [46,47]. The combi-
nation and interaction of genetic susceptibility factors and
environmental exposure is summarized in the concept of
impaired xenobiotic metabolism and sheds first light into the
mechanisms of neurodegeneration. These initial insights
may translate into new therapies for PD patients that take
into account the individual genetic backgrounds reflected in
enzymatic activities [48–50].
Even once associations of PD with environmental factors
were established, it was yet not clear whether there is (inverse)
causality between PD and these factors, e.g. the reverse
association between PD and smoking [51]. One way to
investigate environmental factors and their causality for PD
might be by using so called Mendelian randomisation (MR)
methods.
3. Mendelian randomisation
3.1. Principles of Mendelian randomisation
Association studies are a common tool to investigate
aetiologies of pathologies, however it is now known thatassociation and causality are not equivalent by no means, as
an association between a disease and a risk factor can be
caused by unknown factors (confounders) or the disease can
cause the increased presence of a risk factor (reverse
causation), as represented in Fig. 2A. In order to avoid
confounding factors (selection bias, cofounders, reverse
causation. . .), randomised control trials (RCT), by randomly
assigning study participants in two or more groups, are
considered as gold standard for investigating causality in
prospective clinical trials. Besides the ethical concerns of
exposing subjects deliberately to the investigated risk factor,
these studies have the downside that they are expensive and
time consuming as a longitudinal observation period is
needed. Additionally, RCTs are limited in the number of risk
factors investigated and they only reflect the effect of an
exposure during a certain period of time in the life of the study
participant.
The aim of a MR study is to assess whether a non-genetic/
modifiable environmental exposure is associated with the
investigated pathology by introducing a randomisation method
into an observational study and avoiding the above-mentioned
downsides of RCTs [52]. As shown in a directed acyclic graph
(Fig. 2A), MR is able to test the null hypothesis that the
pathology (outcome) is not caused by an exposure, by assuming
that genetic variants used as instrumental variables (IV)
are robustly associated with the investigated exposure, are
independent of confounders and are associated with the
investigated outcome solely (and linearly, unaffected by
statistical interactions) via the exposure [53]. The randomisa-
tion method in MR studies is based on Mendelian principles
of inheritance [54]. MR studies use genetic variants, such
as single nucleotide polymorphisms (SNPs) as IVs to measure
the effect of an non-genetic exposure on an outcome (Fig. 2A)
[55,56]. This randomisation method of using germline
genetic variants (which are supposed to be randomly distri-
buted during conception in the general population) as varia-
bles, is used for proving causal associations and to accurately
estimate the effect of a lifelong exposure to an environmental/
lifestyle risk factor on an outcome [57], by being less susceptible
to the biases of observational studies [58].
3.2. Mendelian randomisation in Parkinson’s disease
In the past decades, classical epidemiological studies (includ-
ing potential recall biases) could determine some environ-
mental risk factors for PD, for example pesticide usage or head
trauma [59–62]. But also, protective factors having a negative
association with the PD risk, such as smoking, caffeine
drinking or elevated urate levels in serum were identified in
such studies. These negative associations (or potential protec-
tive factors) are widely discussed and MR studies provide a
way to analyse these associations for their causalities and to
shed light on potential protective factors.
Potentially due to its antioxidative effect, elevated plasma
urate levels were shown to have a negative association with
PD risk [63]. A Japanese clinical study had already investigated
whether inosine (a urate precursor) would increase the plasma
urate level of PD patients, without proving causality [64]. Two
independent Danish studies recently used MR methods to
assess causality of PD incidence and metabolic data such as
Fig. 2 – The principles of Mendelian randomisation represented in a directed acyclic graph (A). The example of Parkinson’s
disease is represented in B. Genetic variants of alpha-synuclein (or other) can potentially cause the PD phenotype or even a
‘‘primary personality’’ for a tendency to expose to non-genetic factors (such as cigarette smoking). If cigarette smoking is
‘‘protective factor’’ for PD (causality) or due to this ‘‘primary personality’’ (reverse causality) is debated.
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between elevated plasma urate and a reduced risk for PD was
shown, but MR analysis remained negative and provided no
evidence for a causal relationship between this modifiable risk
factor and the outcome. The initially demonstrated epide-
miological association might therefore be attributed to other
unknown factors than the elevated urate levels, making the
rationale of clinical inosine studies potentially less relevant
[67].
The negative association of PD risk and coffee drinking or
nicotine smoking was previously shown in different epide-
miological studies [68], raising the controversy over whether,
for example, smoking cigarettes reduces the risk for PD, or
PD patients are less likely to become addicted to smoking
because of their underlying ‘‘primary personality’’ (Fig. 2B).
Serum caffeine and its metabolites were even investigated as
potential diagnostic biomarkers for early PD, consistent with
its supposed neuroprotective effect [69]. However, the under-
lying causality is not known yet (neuroprotective substances
absorbed by the lungs or digestive tract are speculated) and an
RCT exposing intentionally subjects to cigarette smoking to
investigate the risk for PD would be highly unethical. Many MR
studies have been conducted as a new approach to investigate
potential protective environmental factors, such as coffee
consumption, and their effect on health [70]. Also high serum
iron levels and a high body mass index (BMI) were shown in
MR studies to have a negative causal effect on PD risk [71,72].
Low LDL cholesterol levels on the other hand, might have acausal effect on lowering the risk for AD, without an effect on
PD risk [73].
A recent MR study on daily coffee consumption and PD risk
could not define a causal effect between these two, but did find
a positive causal association between being a ‘‘morning
person’’ and increased PD risk [74]. The circadian rhythm is
highly determined by genetic variants and the presumption is
that the resulting phenotype ‘‘morning person’’ is more active
in the morning and does not need to drink as much coffee to
start its day. However, the ‘‘night owl’’ (having a lower risk for
PD) would need more coffee in the morning to cope with the
‘‘8 a.m. to 5 p.m.’’ work schedule dictated by the society,
explaining the reduced risk for PD associated with coffee
consumption as an epiphenomenon. This causal association
of the sleep-wake rhythm and PD (or neurodegenerative
diseases in general) makes sense in light of studies showing
amyloid-beta accumulation in sleep deprived brains [75].
3.3. Limitations of Mendelian randomisation
Complementing the classical observational studies by avoiding
their biases, MR is not without its limitations. In order to be
used to assess the effect of a non-genetic risk factor on an
outcome, MR relies on the availability of robust genetic data.
Many GWAS studies have enlightened in the last decades not
only associations with diseases, but also complex measurable
parameters such as body mass index (BMI; [76]), serum level of
metabolites (such as serum uric acid or cholesterol levels;
r e v u e n e u r o l o g i q u e 1 7 5 ( 2 0 1 9 ) 5 9 7 – 6 0 3 601[77,78]), cognitive features or many other behaviour patterns
like diets and habits [79–81]. For example, Yengo and colleagues
analysed GWAS data of about seven hundred subjects using MR
and identified hundreds of exposure-associated SNPs (data
available because of the increasing number of genetic asso-
ciation studies and data banks) [76]. The discovery of new
genetic traits and SNPs and the assessment of causalities are
more accurate if a large sample of genetic data is available.
Therefore, MR studies cannot be used if no SNPs have been
identified to be associated for the exposure, or they don’t have
sufficient power to detect causality if the SNPs don’t explain the
integral exposure variation [57].
4. Conclusion
Mendelian randomisation studies are an efficient method,
complementary to classical association studies, to assess
causalities of modifiable environmental risk factors if suffi-
cient genetic data is available. Therefore, cohorts assessing a
huge array of different clinical data and providing a detailed
genetic characterization are needed in the future to enhance
the power of these MR studies [82]. Avoiding confounder and
reverse causality biases of association studies, MR thus
enables to investigate gene-environmental interactions and
determine potential protective factors to be implemented in
future preventive medicine campaigns. They might offer a
good tool for guiding future clinical RCTS, by avoiding errancy
and waste of research resources.
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